Magnetic nanoparticles have been investigated for biomedical applications for more than 30 years. In medicine they are used for several approaches such as magnetic cell separation or magnetic resonance imaging (MRI). The development of biocompatible nanosized drug delivery systems for specific targeting of therapeutics is the focus of medical research, especially for the treatment of cancer and diseases of the vascular system. In an experimental cancer model, we performed targeted drug delivery and used magnetic iron oxide nanoparticles, bound to a chemotherapeutic agent, which were attracted to an experimental tumour in rabbits by an external magnetic field (magnetic drug targeting). Complete tumour remission could be achieved. An important advantage of these carriers is the possibility for detecting these nanoparticles after treatment with common imaging techniques (i.e. x-ray-tomography, magnetorelaxometry, magnetic resonance imaging), which can be correlated to histology.
Introduction
Magnetic nanoparticles may open up a wide field of possible applications in medicine. Up to now, magnetic nanoparticles have been used in medicine for magnetic separation techniques [1] [2] [3] [4] [5] [6] [7] [8] [9] as contrast agents in magnetic resonance imaging [10] [11] [12] [13] , for local hyperthermia [14] [15] [16] [17] or as magnetic targetable carriers for several drug delivery systems [18] [19] [20] [21] .
For application in biological organisms, these particles have to be biocompatible. It could be shown that, generally, starch-coated magnetic iron oxide nanoparticles are tolerated quite well [22, 23] . Because of this, and because of the fact that these kinds of particles are produced as commercial contrast agents for MRI investigations (Combidex ® Complete tumour remission could be achieved with only 20% of the regular systemic dose: therapy group, n = 5; control group, n = 2 [28] .
Endorem ® , Sinerem ® ), iron oxide nanoparticles seem to be a convenient carrier material for drug targeting systems. This class of particles show superparamagnetic properties and can be attracted by an external magnetic field. Furthermore, nanosized particles are small enough to prevent occlusions of the vascular system, especially the capillaries. The required size of the particles probably has to be smaller than 5 µm [24] . On the other hand, magnetic nanoparticles should not be too small, because of their attractability by an external magnetic field gradient. Investigations of the size-dependent body distribution of these particles have shown that particles larger than 100 nm in diameter are intercepted more by cells of the MPS (mononuclear phagocyte system) than smaller particles [25] . After intravenous application (the regular administration of parenteralia), the magnetic particles can be found in macrophages of the liver, spleen and lung, because of the so-called first-pass effect [26, 27] .
To avoid this effect, we performed our approach for local cancer chemotherapy with starchcoated iron oxide nanoparticles, dispersed in deionized water, with intra-arterial application into the tumour-supplying artery. The magnetic particles were coupled to the chemotherapeutic agent mitoxantrone and attracted and held in the tumour region by a strong external magnetic field gradient after application (magnetic drug targeting). In previous studies, it could be shown that this drug delivery system can cause complete tumuor remission in tumour-bearing rabbits [28] [29] [30] [31] . In addition to that, the applied dose of the drug could be diminished to 20% of the regular systemic dose. Tumour remission was achieved without any negative side-effects, which are common after regular cancer chemotherapy (figure 1). These results indicate the great advantage of this magnetically guided drug delivery system, which is caused by the reduction of the given chemotherapeutic agent and the focused application protecting healthy tissue [21, [32] [33] [34] [35] .
Investigations of the distribution of the particles showed a high accumulation of magnetic particles in the tumuor region, in contrast to other body compartments (i.e. liver or spleen). This was performed by measurements of 59 Fe-nanoparticles, x-ray tomography pictures and magnetorelaxometry of the relaxation signal by superconducting quantum interference detector (SQUID) sensors in correspondence to histological examinations [27, 36, 37] . i.a. 59 Fe-ferrofluids with external magnetic field (n = 2); i.a. 59 Fe-ferrofluids without external magnetic field (n = 1); ts. = tumor side [27] . Investigations concerning the particle distribution showed a high accumulation of the magnetic particles in the tumour region in contrast to other body compartments, i.e. liver or spleen. In experiments using radioactive 59 Fe-nanoparticles, 114 times more activity could be detected in the tumour region after magnetic drug targeting compared to the control without a magnetic field [27] (figure 2).
X-ray-tomography pictures show the iron oxide nanoparticles after magnetic drug targeting in the vascular system of the tumour (figure 3).
The corresponding histological cross sections show the nanoparticles after intra-arterial application in the vascular system of the tumour (figure 4). SQUID-based magnetorelaxometry measurements of the relaxation signal of the nanoparticles proved non-invasively that a high amount of magnetic nanoparticles (∼85%) was accumulated in the tumour region, together with a much smaller accumulation in the liver region [37] (figure 5). The observed slow time decay of the magnetization ( figure 5(b) ) was attributed to Néel relaxation, indicating that the particles in the tumour were immobilized. Additionally the distribution of the chemotherapeutic drug which is the therapeutic agent in this cancer treatment was investigated [27] .
In vitro studies with fluorescence labelling of tumour cell culture have shown the direct binding of mitoxantrone to the cell nucleus, the required place of drug interaction [38] .
Comparing different application modes, high pressure liquid chromatography analysis of the chemotherapeutic agent after magnetic drug targeting proved a 75 times higher concentration of the chemotherapeutic agent in the tumour region compared to the regular systemic administration [27, 39, 40] .
In VX2 tumor cell culture incubated with mitoxantrone for one hour, only DNA-coupled mitoxantrone in the tumour cells was fluorescence positive (figure 6). Fibroblast-like cells in the cell culture do not show any fluorescence [38] .
Despite in vitro and animal experiments, it is necessary that nanoparticles for in vivo applications in human patients need to be manufactured and analysed under the guidelines of pharmaceutical regulations. This is realized for commercially available iron oxide nanoparticle suspensions used as contrast agent in MRI. But these nanoparticle suspensions have to be administered strictly intravenously and highly diluted in deionized water to avoid embolization caused by the loss of the colloidal stability and the formation of bigger conglomerates [24] . The coating and the charge state of nanoparticle suspensions are responsible for their compatibility in the biological organism [26, 41] . With the application of an external magnetic field after intra-arterial drug delivery, a local accumulation of nanoparticles occurs with a potential increase in conglomerate formation and the risk of vessel occlusions.
Therefore we investigated the colloidal stability of the iron oxide nanoparticles used in our experiments under conditions of different physiological and injectable solutions by particle sizing, measurements of zeta potential, electron microscopy and with an in vitro artery model. 
Material and methods

Magnetic nanoparticles
The nanoparticles were manufactured by Chemicell (Berlin, Germany) and consist of iron oxides covered by phosphated starch polymers for colloidal stabilization in deionized water.
Magnetic field
For the experiments, we used a powerful electromagnet with a maximum magnetic field strength of 1.7 T and a magnetic field gradient of 10 T m −1 .
Mitoxantrone (MTX)
The chemotherapeutic agent that was used, coupled to the magnetic nanoparticles, is the anthracendion derivative MTX-HCL (Mitoxantrone, Novantron ® ; Lederle, Wyeth-Pharma, Germany). It inhibits DNA and RNA syntheses and causes DNA-strand breaks by intercalation.
Colloidal stability
Particle sizing.
Particle suspension were diluted 1:100 with distilled water. The size was determined with dynamic laser scattering (DLS, Nicomp 380 ZLS, Santa Barbara, CA, USA). Further DLS investigations were performed with the same dilution in 0.9% NaCl solution, Ringer buffer and physiological electrolyte solution (Tutofosin) to simulate physiological or probable injection parameters.
Zeta potential.
Zeta-potential measurements were performed with the Zeta option of the DLS equipment. Dilutions were the same compared to DLS measurements. Additional to the above-mentioned conditions, the zeta potential was determined in electrolyte-albumine solution (bovine serum albumine, Sigma, Germany) as a potential serum substitute.
Electron microscopy.
Ferrofluids in different solutions (distilled water, 0.9% NaCl) were fixed in 2% Agar (Merck, Darmstadt, Germany). After dehydration with ethanol (Merck) and acetone, the samples were embedded in Epon (Epoxyd resin, Roth, Karlsruhe, Germany).
Artery model.
For this model, we used freshly isolated bovine femoral arteries. The artery is mounted in a tempered circuit (figure 7). As a flow medium, we used Krebs-Ringer buffer pH 7.4 substituted with 0.625% albumine. The artery was placed near the tip of the electromagnet. Nanoparticle suspensions were applied by a side inlet under pulsatile flow. Using a pump, it is possible to simulate different flow velocities and different vessel pressures.
After the magnetization procedure, the outflow was collected. Differences in particle agglomerate diameter were measured by DLS.
Results
We detected an increasing instability of the particle suspension in the presence of physiological salt solutions in the size determination by DLS (table 1) and with zeta-potential measurements (table 2) in comparison to measurements in deionized water.
The results could be confirmed by electron microscopy pictures of the particles suspended in deionized water versus physiological 0.9% NaCl (figure 8).
The same phenomenon was observed in the artery model. The decrease in the zeta potential in the physiological surrounding (Krebs-Ringer buffer pH 7.4 substituted with 0.625% albumine), combined with the applied magnetic field, leads to total decomposition of the nanoparticle suspension (figure 9).
Conclusions and discussion
Investigations of the distribution of the magnetic nanoparticles after intra-arterial infusion and magnetic targeting showed that this drug delivery system is suitable for attracting magnetic iron oxide particles to a respective body compartment (i.e. tumour). This was examined after an extensive manufacturing procedure with radioactive 59 Fe-particles. In a pilot study, we could show that this is also possible non-invasively with common imaging techniques like x-ray tomography and magnetorelaxometry. The results of these imaging techniques were confirmed by histological cross sections. This allows the control of a successful particle accumulation directly after treatment with this form of local chemotherapy.
HPLC studies of tissue samples proved that the distribution of the chemotherapeutic agent follows distribution of the applied nanoparticles and excludes the assumption that the chemotherapeutic agent desorbs too early before the drug carrier reaches the site of action (i.e tumour region). In addition to that, we demonstrated the direct binding of the chemotherapeutic agent in tumour cells with fluorescence detection of the intercalated DNA.
The efficacy of this treatment was only observed after intra-arterial application of the nanoparticles and not after intravenous particle administration [27] .
Due to the intra-arterial application of magnetic nanoparticle suspensions, other facts have to be taken into consideration. All intra-arterial interventions are associated with a potential thrombotic risk, more than after intravenous application. In previous studies, we already had indications for a partial defragmentation of ferrofluid suspensions in vivo due to particle enrichment in the lung [27] . Two possible mechanisms for a thrombotic event after intra-arterial delivery are imaginable. First, the surface of the particle suspension causes a direct activation of the thrombotic system. This mechanism is also present after intravenous application and depends on the interaction of the particle surface with the activators of the coagulation cascade. Second, instability of particle solution with the formation of greater agglomerates may lead to an occlusion of capillaries proximal to the application side and a subsequent occlusion of the artery, which may lead to life-threatening situations. This mechanism is much more relevant after intra-arterial application. Therefore nanoparticle suspensions for tumour treatment in humans have to be stable under physiological conditions. To achieve pharmaceutically acceptable drug delivery systems for this promising therapeutic concept, further modifications of the particle surface and colloidal stability are necessary to apply this cancer therapy in human patients.
